228 related articles for article (PubMed ID: 21969814)
1. Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.
Bekes EM; Deryugina EI; Kupriyanova TA; Zajac E; Botkjaer KA; Andreasen PA; Quigley JP
Neoplasia; 2011 Sep; 13(9):806-21. PubMed ID: 21969814
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion.
Conn EM; Botkjaer KA; Kupriyanova TA; Andreasen PA; Deryugina EI; Quigley JP
Am J Pathol; 2009 Oct; 175(4):1638-52. PubMed ID: 19729488
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
4. Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation.
Madsen MA; Deryugina EI; Niessen S; Cravatt BF; Quigley JP
J Biol Chem; 2006 Jun; 281(23):15997-6005. PubMed ID: 16611636
[TBL] [Abstract][Full Text] [Related]
5. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
Le DM; Besson A; Fogg DK; Choi KS; Waisman DM; Goodyer CG; Rewcastle B; Yong VW
J Neurosci; 2003 May; 23(10):4034-43. PubMed ID: 12764090
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
7. Pro-urokinase-type plasminogen activator is a substrate for hepsin.
Moran P; Li W; Fan B; Vij R; Eigenbrot C; Kirchhofer D
J Biol Chem; 2006 Oct; 281(41):30439-46. PubMed ID: 16908524
[TBL] [Abstract][Full Text] [Related]
8. Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.
Botkjaer KA; Deryugina EI; Dupont DM; Gårdsvoll H; Bekes EM; Thuesen CK; Chen Z; Ploug M; Quigley JP; Andreasen PA
Mol Cancer Res; 2012 Dec; 10(12):1532-43. PubMed ID: 23038812
[TBL] [Abstract][Full Text] [Related]
9. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin.
Festuccia C; Guerra F; D'Ascenzo S; Giunciuglio D; Albini A; Bologna M
Int J Cancer; 1998 Jan; 75(3):418-31. PubMed ID: 9455804
[TBL] [Abstract][Full Text] [Related]
10. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
Petersen LC
Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
[TBL] [Abstract][Full Text] [Related]
12. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
List K; Jensen ON; Bugge TH; Lund LR; Ploug M; Danø K; Behrendt N
Biochemistry; 2000 Jan; 39(3):508-15. PubMed ID: 10642175
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
Dong Z; Saliganan AD; Meng H; Nabha SM; Sabbota AL; Sheng S; Bonfil RD; Cher ML
Neoplasia; 2008 May; 10(5):439-49. PubMed ID: 18472961
[TBL] [Abstract][Full Text] [Related]
15. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Meissauer A; Kramer MD; Schirrmacher V; Brunner G
Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
[TBL] [Abstract][Full Text] [Related]
16. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
17. Plasmin modulators, aprotinin and anti-catalytic plasmin antibody, efficiently inhibit destruction of bovine vascular endothelial cells by choriocarcinoma cells.
Sugimura M; Kobayashi H; Terao T
Gynecol Oncol; 1994 Mar; 52(3):337-46. PubMed ID: 7512520
[TBL] [Abstract][Full Text] [Related]
18. Urokinase regulates embryonic cardiac cushion cell migration without converting plasminogen.
Gorny KN; Brauer PR
Anat Rec; 1999 Nov; 256(3):269-78. PubMed ID: 10521785
[TBL] [Abstract][Full Text] [Related]
19. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-type plasminogen activator regulates cranial neural crest cell migration in vitro.
Agrawal M; Brauer PR
Dev Dyn; 1996 Nov; 207(3):281-90. PubMed ID: 8922527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
